A New Class of Multimerization Selective Inhibitors of HIV-1 Integrase
Open accessThe DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
The quinoline-based allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are promising candidates for clinically useful antiviral agents. Studies using these compounds have highlighted the role of IN in both early and late stages of virus replication. However, dissecting the exact mechanism of action of the quinoline-based ALLINIs has been complicated by the multifunctional nature of these inhibitors because they both inhibit IN binding with its cofactor LEDGF/p75 and promote aberrant IN multimerization with similar potencies in vitro. Here we report design of small molecules that allowed us to probe the role of HIV-1 IN multimerization independently from IN-LEDGF/p75 interactions in infected cells. We altered the rigid quinoline moiety in ALLINIs and designed pyridine-based molecules with a rotatable single bond to allow these compounds to bridge between interacting IN subunits optimally and promote oligomerization. The most potent pyridine-based inhibitor, KF116, potently (EC50 of 0.024 µM) blocked HIV-1 replication by inducing aberrant IN multimerization in virus particles, whereas it was not effective when added to target cells. Furthermore, KF116 inhibited the HIV-1 IN variant with the A128T substitution, which confers resistance to the majority of quinoline-based ALLINIs. A genome-wide HIV-1 integration site analysis demonstrated that addition of KF116 to target or producer cells did not affect LEDGF/p75-dependent HIV-1 integration in host chromosomes, indicating that this compound is not detectably inhibiting IN-LEDGF/p75 binding. These findings delineate the significance of correctly ordered IN structure for HIV-1 particle morphogenesis and demonstrate feasibility of exploiting IN multimerization as a therapeutic target. Furthermore, pyridine-based compounds present a novel class of multimerization selective IN inhibitors as investigational probes for HIV-1 molecular biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Counterintuitively, the underlying mode of ALLINI action is not via inhibition of integration140,142,174–177,179–181.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MINI compounds moreover were ineffective at inhibiting the early stage of HIV-1 infection177.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“The common biochemical consequence of ALLINI binding is aberrant HIV-1 IN hyper-multimerization140,142,174–181.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“Compounds of the latter class do not effectively antagonise HIV-1 IN-LEDGF/p75 binding.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“Consistent with the known role of LEDGF/p75 in HIV-1 integration targeting, genic integration targeting during HIV-1 ingress was suppressed by ALLINIs177,184,185.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915 · cited 1×
“Coot program [65] was used for the subsequent refinement and building of the structure.”
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742 · cited 1×
“Refmac5 [66] of the CCP4 package was used for the restraint refinement.”
MethodIn Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics
Berne, B. J., & Pecora, R. (1976) · CERN Document Server (European Organization for Nuclear Research) · Cited by 2,856
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., & Martin, M. A. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,834 · cited 1×
“Replication competent HIV-1 was generated using pNL4-3 [68].”
MethodHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832 · cited 3×
“Since LEDGF/p75 is the primary cellular factor responsible for targeting HIV-1 integration to actively transcribed units [58,59], our findings indicate that the treatment of target cells with GS-B likely inhibits IN-LEDGF/p75 binding in the infected cells.”
BackgroundSelf-citationConnor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995) · Virology · doi:10.1006/viro.1995.1016 · Cited by 1,253
Research works printed but not linked: 4
- Brown PO (1997) Integration. In: Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Plainview, NY: Cold Spring Harbor Laboratory. pp. 161–204.
- Fenwick CW, Tremblay S, Wardrop E, Bethell R, Coulomb R, <etal>et al</etal>.. (2011) Resistance Studies with HIV-1 Non-Catalytic Site Integrase Inhibitors. International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies. Los Cabos, Mexico. pp. A9.
- Tsantrizos YS, Boes M., Brochu C., Fenwick C., Malenfant E., Mason S., Pesant M. (2007) Inhibitors of Human Immunodeficiency Virus Replication. International Patent Application PCT/CA2007/000845. pp. 1–116.
- Yoakim C, Bailey MD, Bilodeau F, Carson RJ, Fader L, <etal>et al</etal>.. (2010) Inhibitors of human immunodeficiency virus replication. International Patent Application PCT/CA2010/000707. pp. 1–195.
Cited by
Items 101–131 of 131
Montermoso, S., Eilers, G., Allen, A., Sharp, R., Hwang, Y., Bushman, F. D., Gupta, K., & Duyne, G. D. V. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169224 · Cited by 5
“These inhibitors bind to a pocket on IN where the host cofactor LEDGF/p75 binds, thereby disrupting LEDGF-dependent integration site targeting in the early phase of replication [4,5,9–11 , 13– 15”
Self-citationReza, R., Dutta, T., Ghosh, N. N., Baildya, N., Das, R. K., & Khan, A. A. (2024) · Proceedings of the Indian National Science Academy · doi:10.1007/s43538-024-00331-9 · Cited by 4
“These derivatives inhibit both RNA (HIV-1, Ebola Virus (EBOV) (Sharma et al. 2014; Cui et al. 2018), Respiratory Syncytial Virus (RSV) (Carta, et al. 2011), hepatitis C virus (HCV) (Carta, et al. 2011), and influenza A virus (IAV) (Wang et al. 2020b; Wang et al. 2021) and DNA such as herpes simplex…”
HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence
Zhao, X. Z., Métifiot, M., Kiselev, E., Kessl, J. J., Maddali, K., Marchand, C., Kvaratskhelia, M., Pommier, Y. G., & Burke, T. R. (2018) · Molecules · doi:10.3390/molecules23081858 · Cited by 4
Self-citationZhang, Z., Yuan, S., Xu, S., Guo, D., Chen, L., Hou, W., & Wang, M. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00311-5 · Cited by 4
Thangsunan, P., Wongsaipun, S., Kittiwachana, S., & Suree, N. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1580219 · Cited by 3
“…previously reported (Christ et al., 2010; 2012; Feng et al., 2013; Kessl et al., 2012; Le Rouzic et al., 2013; Li et al., 2014; Serrao, Debnath, et al., 2013; Serrao, Xu, et al., 2013; Sharma et al., 2014) targeting the LEDGF/p75 binding site of IN were docked onto the interface cleft accordingly.”
MethodCiubotaru, M., Musat, M. G., Surleac, M. D., Ionita, E., Petrescu, A., Abele, E., & Abele, R. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666180406114405 · Cited by 3
Gordon, C. P., Dalton, N., Vandegraaff, N., Deadman, J. J., Rhodes, D. I., Coates, J. A. V., Pyne, S. G., Griffith, R., Bremner, J. B., & Keller, P. A. (2017) · Tetrahedron · doi:10.1016/j.tet.2017.11.052 · Cited by 2
Drug Design Methods to Regulate Protein–Protein Interactions
Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_6 · Cited by 4
Hao, M., Imamichi, T., & Chang, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031809 · Cited by 1
Adachi, K., Manabe, T., Yamasaki, T., Suma, A., Ogoshi, Y., Takahashi, A., Orita, T., Nomura, A., Adachi, T., Ohata, Y., et al. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118526 · Cited by 1
Nakamura, T., Campbell, J. R., Moore, A. R., Otsu, S., Aikawa, H., Tamamura, H., & Mitsuya, H. (2016) · Journal of Virological Methods · doi:10.1016/j.jviromet.2016.07.023 · Cited by 1
“…al., 2012; Desimmie et al., 2013; Christ et al., 2012), in particular, certain LEDGINs exert anti-viral effects through modulation of IN multimerization rather than by inhibiting IN-LEDGF/p75 interactions (Le Rouzic et al., 2013; Jurado et al., 2013; Balakrishnan et al., 2013; Sharma et al., 2014).”
BackgroundIdentification of specific phylogenetic properties of HIV-1 M and O integrases
Toccafondi, E. (2022) · theses.fr (ABES) · doi:10.70675/2facab6ezc20az472dz8350z9fb6e718e1d4 · Cited by 1
Kalathiya, U., Padariya, M., & Bagiński, M. (2018) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1646
Amadori, C. (2016) · theses.fr (ABES) · doi:10.70675/2da75a32z2820z4ceaz8909zee47e88e36ee
“La fixation des INLAIs sur le site d’interaction entre le domaine IBD de LEDGF sur l’interface du dimère CCD IN induit l’inhibition de cette interaction mais également une diminution des réactions de 3’ processing et de transfert de brin médiées par l’IN in vitro [339,340,341,342,345].”
BackgroundInfluentialCarta, F., & Sechi, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823974-2.00006-1
Tocco, G., Laus, A., Casula, M., Caboni, P., Beutler, J. A., Tramontano, E., & Esposito, F. (2025) · Molecules · doi:10.3390/molecules30244709
“At present, the predominant strategies for allosteric inhibition of IN primarily concentrate on modifying IN oligomerization by interfering with the assembly of oligomeric complexes [11–13] or encouraging abnormal IN multimerization [14–17].”
Caractérisation des voies d’échappement aux inhibiteurs d’intégrase du VIH-1
Thierry, E. (2015) · theses.fr (ABES) · doi:10.70675/602eaec1z5d9az4bb2za08dz10755e91efc2
HIV-1 Integrase During the Time: History of Drugs and Effort for the New Inhibitors’ Identification
Esposito, F., Saccoliti, F., Patacchini, E., & Santo, R. D. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_180
Molecular basis of the interaction between HIV-1 integrase and viral RNA
Rocchi, C. (2022) · theses.fr (ABES) · doi:10.70675/56a488fez1f79z4d34z81d9z905314a2ca30
Protein‐Protein Interaction as an Efficient Target to Inhibit HIV‐1 Integrase
Zarghi, A., & Hajimahdi, Z. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70221
Mapping the TAR vRNA Interaction with HIV-1 Integrase
Sun, J., Yadav, R., Catmakas, T., Fisher, L., Fitzkee, N. C., & Kessl, J. J. (2026) · Viruses · doi:10.3390/v18060657
“For sucrose density gradient fractionation [12,13], cell-free virions from transfected HEK293T cells were concentrated by ultracentrifugation over a 25% sucrose cushion, pelleted virions were lysed with 0.5% Triton X-100 and were centrifuged through a 30–70% linear sucrose density gradient.”
InfluentialSelf-citationSaccoliti, F., Patacchini, E., Cara, E., Zarbo, L., Messore, A., Albano, A., Ruggieri, G., Madia, V. N., Scipione, L., Costi, R., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70428 · Cited by 1
BindingDB (2020) · UC San Diego · doi:10.7270/q2pc352q
BindingDB Entry 50010092: Indole-based allosteric inhibitors of HIV-1 integrase.
BindingDB (2021) · UC San Diego · doi:10.7270/q2r214vc
BindingDB Entry 50009955: Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.
BindingDB (2021) · UC San Diego · doi:10.7270/q2ks6w19
Metadata
- Authors
- Sharma, A., Slaughter, A., Jena, N., Feng, L., Kessl, J. J., Fadel, H. J., Malani, N., Male, F., Wu, L., Poeschla, E., Bushman, F. D., Fuchs, J. R., & Kvaratskhelia, M.
- Affiliations
- The Ohio State University (US)
- Mayo Clinic (US)
- University of Pennsylvania (US)
- Corresponding author
- Kvaratskhelia, Mamuka
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-29
- Volume
- 10
- Issue
- 5
- Pages
- e1004171
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC4038613
- OpenAlex
- W2044894228
- Cited by
- 124
- References
- 80
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 9 · 2023: 10 · 2022: 14 · 2021: 13 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 8 · 2016: 15 · 2015: 9 · 2014: 5
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Gilead Sciences
- National Institutes of Health (AI062520, GM103368)
- National Institute of General Medical Sciences (P50GM103368)
- National Institute of Allergy and Infectious Diseases (R01AI062520, R01AI077344, R01AI104483, R01AI052845, R01AI110310, R21AI110270)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1 integrase, integrase multimerization, LEDGF/p75, HIV-1 integration, antiviral drug design
- MeSH terms
- Antiviral Agents, Cell Line, Humans, Protein Binding, Quinolines, Virus Replication, HIV-1, Virus Integration, HIV Integrase, HIV Integrase Inhibitors, Intercellular Signaling Peptides and Proteins, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.